Emisphere Technologies (EMIS.OB) Extends Exclusive Agreement with Novo Nordisk (NVO) for Diabetes Treatment

QualityStocks would like to highlight Emisphere Technologies (OTCBB: EMIS). Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen(R) Technology.

In the company’s news yesterday,

Emisphere Technologies Inc. and Novo Nordisk A/S announced their extended partnership to develop and commercialize oral formulations of Novo Nordisk’s insulins, which have the potential of treating diabetes, using Emisphere’s Eligen® technology.

The exclusive development and license agreement is in line with Novo Nordisk’s overall dedication to diabetes research.

“This is an encouraging agreement on a promising technology for oral administration of proteins. We are delighted to continue working with Emisphere and their Eligen® Technology. It fits very well with Novo Nordisk’s strategy within diabetes research,” Peter Kurtzhals, senior vice president of Diabetes Research Unit at Novo Nordisk stated in the press release.

The insulin agreement includes $57.5 million in potential product development. Emisphere will receive $5 million upon signing, as well as sales milestone payments and royalties on sales.

Today’s announced agreement is the second license agreement between the two companies. The first agreement was signed for the development of oral formulations of GLP-1 receptor agonists in 2008 with a potential drug currently in a phase 1 clinical trial.

Michael V. Novinski, president and CEO of Emisphere said the extended partnership has several important points for Emisphere.

“To date, our collaboration with Novo Nordisk has been very productive, and today’s agreement has the potential to offer significant new solutions to millions of people with diabetes worldwide. Finally, it also serves to further validate our Eligen® Technology,” Novinski stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.